Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

PURPOSE: To determine the maximum-tolerated dose (MTD) and assess safety, pharmacokinetics, pharmacodynamics, and evidence of antitumor activity of RO4929097, a gamma secretase inhibitor of Notch signaling in patients with advanced solid malignancies. PATIENTS AND METHODS: Patients received escalati...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Tolcher, Anthony W., Messersmith, Wells A., Mikulski, Stanislaw M., Papadopoulos, Kyriakos P., Kwak, Eunice L., Gibbon, Darlene G., Patnaik, Amita, Falchook, Gerald S., Dasari, Arvind, Shapiro, Geoffrey I., Boylan, John F., Xu, Zhi-Xin, Wang, Ka, Koehler, Astrid, Song, James, Middleton, Steven A., Deutsch, Jonathan, DeMario, Mark, Kurzrock, Razelle, Wheler, Jennifer J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2012
Gaiak:
ORIGINAL REPORTS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5950496/
https://ncbi.nlm.nih.gov/pubmed/22529266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.36.8282
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak